RubrYc Therapeutics

About RubrYc Therapeutics

RubrYc Therapeutics, Inc. operated as a biotherapeutics discovery company, leveraging artificial intelligence to create antibody-based drugs. Founded in 2017 by Isaac J. Bright, Matthew Greving, and Mohan Srinivasan, the company officially spun out of immunomics firm HealthTell, Inc. in April 2018. This launch was supported by an initial $10 million Series A financing from investors including Third Point Ventures and Paladin Capital Group. The founders combined expertise from diverse fields; Dr. Bright has a background in medicine, business, and venture capital, holding an MD from Stanford and an MBA from Wharton, while Dr. Greving brought experience in biochemistry and software engineering, with a Ph.D. from Arizona State University. This blend of skills informed the company's core strategy.

The company's business model centered on both developing its own pipeline of therapeutic candidates and forming partnerships with pharmaceutical companies to co-discover new drugs. Its primary clients were biotechnology and pharmaceutical firms seeking to accelerate preclinical antibody discovery. RubrYc generated revenue through upfront payments, research and development milestones, and potential royalties from collaborations, such as its agreements with Zai Labs and iBio. By August 2021, the company had raised a total of $19.8 million.

RubrYc's core asset was its Interface Discovery Engine™, a platform that integrated machine learning, computational biology, and chemical library synthesis to identify antibodies with high selectivity for specific epitopes—the parts of a target protein where antibodies bind. This AI-driven approach was designed to model subdominant and conformational epitopes, which are often missed by traditional screening methods, to create treatments for hard-to-target cancers and autoimmune diseases. A key capability was using engineered molecules to steer the immune response toward desired epitopes, a method validated in a blinded study with Merck. This allowed RubrYc to address significant challenges in drug discovery, such as creating an antibody that effectively binds to the CD25 protein without disrupting essential IL-2 signaling. In September 2022, RubrYc's journey as an independent entity concluded when it was acquired by its partner, iBio, Inc., in a deal valued at $1 million upfront in stock, with potential for future milestone payments. The acquisition integrated RubrYc's AI platform and its pipeline of immuno-oncology candidates into iBio's operations.